Sign up Australia
Proactive Investors - Run By Investors For Investors

Sareum Holdings shares spike ahead of US poster presentations

Currently, SRA737 is in phase I/II clinical trials as a single therapy to treat certain stress-driven cancers
Sareum Holdings shares spike ahead of US poster presentations
The writing's on the wall: Delegates at a cancer conference will be told SRA737 “synergises” with PARP inhibitor, niraparib

Shares in Sareum Holdings PLC (LON:SAR) rose 9% ahead of poster presentations at a key cancer conference by partner Sierra Oncology.

Sierra is the licence holder for Sareum-developed SRA737. The posters will outline pre-clinical results from its research, including late breaking data. They will be on show at the American Association of Cancer Research annual meeting in Chicago.

WATCH: Sareum Holdings PLC heartened by Sierra Oncology progress

Poster one will reveal that checkpoint kinase-1 inhibitor SRA737 is active in both PARP inhibitor-resistant and CCNE1 high-grade serous ovarian cancers.

Synergies with PARP inhibitor

Poster two will inform delegates the drug “synergises” with PARP inhibitor, niraparib, to kill carcinoma cells via multiple cell death pathways.

PARP inhibitors prevent cancer cells from repairing themselves. PARP stands for poly-ADP ribose polymerase and is found in human cells.

Currently, SRA737 is in Phase I/II clinical trials as a single therapy to treat certain stress-driven cancers.

Sierra is also preparing to test its potential in combination with niraparib to tackle hard-to-treat forms of prostate cancer. 

The shares rose 0.045p to 0.9p.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
scientist with vial
August 09 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use